Ajmaline (Wolfina)

An alkaloid found in the root of RAUWOLFIA SERPENTINA, among other plant sources. It is a class 1-A antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials.

Also Known As:

Networked: 381 relevant articles (17 outcomes, 36 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Brugada, Pedro: 21 articles (01/2022 - 01/2004)
2.	Chierchia, Gian-Battista: 11 articles (01/2022 - 05/2010)
3.	de Asmundis, Carlo: 11 articles (01/2022 - 05/2010)
4.	Behr, Elijah R: 8 articles (01/2022 - 05/2009)
5.	Sarkozy, Andrea: 8 articles (03/2014 - 11/2005)
6.	Tan, Hanno L: 7 articles (01/2021 - 01/2010)
7.	Pappone, Carlo: 7 articles (01/2021 - 05/2017)
8.	Ciconte, Giuseppe: 7 articles (01/2020 - 12/2013)
9.	Conte, Giulio: 6 articles (01/2022 - 12/2013)
10.	Sorgente, Antonio: 6 articles (01/2022 - 05/2010)

Related Diseases

1.	Ventricular Tachycardia 12/01/1969 - "[A case of ventricular tachycardia treated successfully with ajmaline]." 05/01/1985 - "Efficacy of intravenous ajmaline in ventricular tachycardia." 01/01/2018 - "Overall, before ajmaline testing, 53.4% of patients had ventricular tachyarrhythmia inducibility, which was more frequent in group 1 (65.9%) than in group 2 (42.7%; p < 0.001). " 01/01/2015 - "Ajmaline-induced sustained ventricular tachycardia occurred in one patient with BrP, who finally received an ICD. " 09/01/2013 - "Here, we present a rare case of monomorphic ventricular tachycardia, which was observed during the ajmaline challenge test. "
2.	Cardiac Arrhythmias (Arrythmia) 01/01/1986 - "Ajmaline infusion produced in 40% of the cases a total suppression and in 100% a significant improvement of malignant ventricular arrhythmia. " 04/01/1989 - "Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset." 04/01/1975 - "The antiarrhythmic efficacy of ajmaline has been evaluated in three experimental models of cardiac arrhythmias in the dog. " 12/02/1963 - "[CLINICAL STUDIES ON THE THERAPEUTIC VALUE OF AJMALINE IN CARDIAC ARRHYTHMIAS]." 11/15/2021 - "dST-Tiso Interval, a Novel Electrocardiographic Marker of Ventricular Arrhythmia Inducibility in Individuals With Ajmaline-Induced Brugada Type I Pattern."
3.	Brugada Syndrome 11/01/2017 - "We describe a unique case in which a patient developed inferior J waves with an early repolarization-type electrocardiogram following successful epicardial infundibular substrate ablation (which eliminated the Brugada syndrome electrocardiogram on ajmaline challenge). " 01/01/2004 - "Our results support the hypothesis that (1) sudden unexpected death syndrome and Brugada syndrome are the same disease; (2) male predominance of the phenotype observed in sudden unexpected death syndrome does not apply to this family, suggesting that factors other than the specific mutation determine the gender distinction; and (3) ajmaline may provide false-positive results. " 12/19/2022 - "This study aimed to investigate the predictive value of T-peak to T-end interval and corrected T-peak to T-end interval for predicting the positive response of the ajmaline challenge test in suspected Brugada syndrome patients. " 03/02/2021 - "Evidence-based studies clearly showed that a positive ajmaline test does not provide any additional information on the risk stratification for major ventricular arrhythmic events on asymptomatic individuals with a non-diagnostic Brugada ECG pattern." 01/01/2018 - "This study aimed to assess the impact of systematic ajmaline provocation testing using high right precordial leads (RPLs) on the diagnostic yield of Brugada syndrome (BrS) in a large cohort of SADS families. "
4.	Wolff-Parkinson-White Syndrome (Wolf-Parkinson-White Syndrome) 06/01/1980 - "We conclude that ajmaline is specifically effective and safe in the treatment of the WPW syndrome." 01/01/1989 - "In a patient with the Wolff-Parkinson-White syndrome, the existence of dual accessory pathways, both right-sided, was suspected during ajmaline test and confirmed during electrophysiologic study. " 04/01/1986 - "Comparison of exercise and ajmaline tests with electrophysiologic study in the Wolff-Parkinson-White syndrome." 06/01/1980 - "Ajmaline in WPW syndrome: an electrophysiologic study." 03/03/1995 - "[Ajmaline test in Wolff-Parkinson-White syndrome]."
5.	Tachycardia (Tachyarrhythmias) 01/19/2001 - "The aims of the present study were (1) to determine whether ajmaline administration modifies the rate-dependent properties of the AV node and (2) to correlate these changes with the actions of ajmaline on an in vitro model of AV re-entrant tachycardia. " 04/01/2000 - "At the electrophysiology study, a prolonged HV interval was observed at baseline, and the tachycardia could be reproduced after ajmaline infusion. " 02/01/2013 - "Re-entry tachycardia occurred a second time six days after ablation, and as before, it was stopped only with ajmaline. " 01/19/2001 - "(3) These changes play a role in ajmaline's actions on experimental AV re-entrant tachycardia. " 01/19/2001 - "AV re-entrant tachycardia was sustained when AV effective refractory period divided to tachycardia cycle length was less than 1, ajmaline suppressed AV re-entrant tachycardia by increasing the slope of the AV effective refractory period divided to tachycardia cycle length versus tachycardia rate relation, causing the critical ratio of 1 to be attained at a slower rate. "

Related Drugs and Biologics

1.	Lidocaine (Xylocaine)
2.	Anti-Arrhythmia Agents
3.	Procainamide (Procan)
4.	Propafenone (Rythmol)
5.	Antibodies
6.	Alkaloids
7.	Isoproterenol (Isoprenaline)
8.	Ajmaline (Wolfina)
9.	Flecainide (Tambocor)
10.	Quinidine (Chinidin)

Related Therapies and Procedures

1.	Therapeutics
2.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
3.	Intravenous Administration
4.	Intravenous Injections
5.	Defibrillators (Defibrillator)